Skip to main content
“My treatment is specific for my type of lung cancer” – METex14, Meet Doug
How do you test for MET exon 14 skipping?

MET exon 14 skipping can be detected by an FDA-approved comprehensive biomarker test. If you’re currently taking TABRECTA, your doctor ran a comprehensive biomarker test and your tumor tested positive for MET exon 14 skipping. If you haven’t been tested for MET exon 14 skipping, learn how comprehensive biomarker testing can help inform your treatment options.

What is biomarker testing?

Biomarker testing can help you find out more about your type of lung cancer. This kind of test looks for specific noninherited gene mutations in your DNA that have been linked to cancer growth.

Comprehensive biomarker tests look for multiple genetic mutations that may be found in your type of cancer in one test, including mutations that lead to MET exon 14 skipping.

Many cancer organizations encourage patients with advanced-stage cancer to ask their doctors about comprehensive biomarker testing.

Biomarker testing can be done with a biopsy (a tissue sample from a tumor) or a blood test (also called liquid biopsy or plasma test). Your doctor may be able to reuse tissue from a previous biopsy when testing your mNSCLC for biomarkers.

The results of your test can help you and your doctor find a treatment that is specific for your type of cancer. Ask your doctor about taking a comprehensive biomarker test.

Important Safety Information

TABRECTA may cause serious side effects. Tell your health care provider right away if you get any of the following:

  • Lung or breathing problems. TABRECTA may cause inflammation of the lungs that can cause death. Tell your health care provider right away if...

Approved Use

TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body (metastatic), and 
  • whose tumors have an abnormal mesenchymal ...